Calidi Biotherapeutics Sets Virtual Annual Meeting, Proposes Reverse Split

TL;DR

**Calidi's proposed reverse stock split is a high-stakes gamble to prop up its stock, signaling potential underlying weakness.**

AI Summary

Calidi Biotherapeutics, Inc. (CLDWW) has filed a DEF 14A proxy statement for its virtual Annual Meeting on July 9, 2025, at 9:30 a.m. Pacific Time. Key proposals include the election of directors, ratification of auditors, a Reverse Stock Split Proposal, and an amendment to the 2023 Plan. The company, headquartered at 4475 Executive Drive, Suite 200, San Diego, CA, is operating in the biological products sector. Stockholders as of May 19, 2025, are eligible to vote on these critical proposals. The virtual format aims to enhance stockholder access and participation, with voting and question submission available via live audio webcast at https://meetings.lumiconnect.com/200-624-854-268 using password 'calidi2025'. The Board of Directors recommends a 'FOR' vote on all proposals, including the potentially impactful Reverse Stock Split Proposal and the 2023 Plan Amendment. Specific financial figures for revenue and net income are not detailed in this DEF 14A filing, which focuses on meeting logistics and proposals.

Why It Matters

This DEF 14A filing is crucial for Calidi Biotherapeutics investors as it outlines proposals that could significantly impact share structure and executive compensation, particularly the Reverse Stock Split Proposal and the 2023 Plan Amendment. A reverse stock split often aims to boost share price to meet exchange listing requirements or attract institutional investors, but can also signal underlying financial challenges. The 2023 Plan Amendment could alter equity incentives for employees and executives, affecting talent retention and operational focus. Competitively, these moves could position Calidi to better compete for capital in the biotech sector, where robust funding and a stable share price are vital for drug development.

Risk Assessment

Risk Level: high — The inclusion of a Reverse Stock Split Proposal (Proposal 3) indicates a high risk level. Reverse stock splits are often implemented by companies whose stock price has fallen significantly, potentially below exchange minimums, and can lead to further price volatility or a perception of distress among investors. While the filing doesn't provide specific financial numbers, the need for such a proposal is a strong indicator of potential financial or market challenges.

Analyst Insight

Investors should carefully review the full proxy statement, particularly details on the Reverse Stock Split Proposal and the 2023 Plan Amendment. Consider voting against the reverse stock split if you believe it's a temporary fix without fundamental business improvements, and evaluate the 2023 Plan Amendment's impact on dilution and executive incentives.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Executive Compensation

Key Numbers

• July 9, 2025 — Annual Meeting Date (Date stockholders will vote on key proposals)
• May 19, 2025 — Record Date (Date by which stockholders must own shares to vote)
• Proposal 3 — Reverse Stock Split (Key proposal that could significantly alter share structure)
• Proposal 4 — 2023 Plan Amendment (Proposal affecting equity compensation for employees and executives)

Key Players & Entities

• Calidi Biotherapeutics, Inc. (company) — Registrant filing the DEF 14A
• July 9, 2025 (date) — Date of the virtual Annual Meeting of Stockholders
• 9:30 a.m. Pacific Time (time) — Start time of the virtual Annual Meeting
• May 19, 2025 (date) — Record date for stockholders entitled to vote
• 4475 Executive Drive, Suite 200, San Diego, California 92121 (address) — Business address of Calidi Biotherapeutics, Inc.
• Proposal 3 (other) — Reverse Stock Split Proposal
• Proposal 4 (other) — 2023 Plan Amendment Proposal
• Board of Directors (person) — Recommends voting 'FOR' all proposals
• United States Securities and Exchange Commission (regulator) — Governing body for the DEF 14A filing
• 001-40789 (other) — SEC File Number for Calidi Biotherapeutics, Inc.

FAQ

Industry Context

Calidi Biotherapeutics operates in the biological products sector, focusing on developing novel therapeutics. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Companies in this space often compete on innovation, intellectual property, and the ability to navigate complex clinical trials and FDA approvals.

Regulatory Implications

As a biotechnology company, Calidi Biotherapeutics is subject to stringent regulations from bodies like the FDA. Any delays in clinical trials, manufacturing issues, or adverse safety findings could lead to significant regulatory setbacks and impact the company's ability to bring its products to market.

What Investors Should Do

1. Review the Proxy Statement carefully.
2. Vote on all proposals.
3. Participate in the virtual Annual Meeting.

Key Dates

• 2025-07-09: Annual Meeting of Stockholders — Stockholders will vote on critical proposals including director elections, auditor ratification, a reverse stock split, and an amendment to the 2023 Plan.
• 2025-05-19: Record Date — Establishes the eligibility of stockholders to vote at the Annual Meeting.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC, providing detailed information about matters to be voted on at a company's annual meeting. (This document outlines the proposals and information necessary for stockholders to make informed voting decisions at Calidi Biotherapeutics' annual meeting.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating them. (Proposal 3 at the annual meeting, this could significantly impact the share structure and per-share value of Calidi Biotherapeutics.)

2023 Plan Amendment

A proposed change to the company's existing equity incentive plan, likely affecting stock options or grants. (Proposal 4, this amendment will influence the company's equity compensation strategy for employees and executives.)

Virtual Meeting

A shareholder meeting conducted entirely online, allowing remote participation. (Calidi Biotherapeutics is holding its annual meeting virtually to enhance stockholder access and participation.)

Year-Over-Year Comparison

This filing is a proxy statement for the 2025 Annual Meeting. As specific financial performance metrics like revenue and net income are not detailed within this DEF 14A, a direct comparison of financial performance against a prior period is not possible from this document alone. However, the focus on proposals such as a reverse stock split and plan amendments suggests potential strategic shifts or responses to market conditions that may differ from previous periods.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 23, 2025 by Board of Directors regarding Calidi Biotherapeutics, Inc. (CLDWW).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR